Tags

Type your tag names separated by a space and hit enter

Survey of management of acquired nystagmus in the United Kingdom.
Eye (Lond). 2007 Sep; 21(9):1194-7.E

Abstract

PURPOSE

To determine the current management of acquired nystagmus by ophthalmologists and neurologists.

METHODS

Questionnaires were sent to ophthalmologists (850) and neurologists (434) in the United Kingdom. Estimated numbers of patients seen with acquired nystagmus, treatment options used, and the results of treatment of the patients were collected.

RESULTS

Response rate was 37% for ophthalmologists and 34% for neurologists. The most common causes of acquired nystagmus were estimated to be multiple sclerosis and stroke. 58% of ophthalmologists and 94.5% of neurologists reported seeing patients with nystagmus. The most commonly used medical treatment was gabapentin and baclofen. Other drugs used were clonazepam, carbamazepine, benzhexol, ondansetrone, buspirone, memantine, and botulinum toxin (n=3). Eleven ophthalmologists and 52 neurologists noted symptomatic improvement with medical treatment. Eleven ophthalmologists and 44 neurologists noted improvement in visual acuity (VA). Occurrence of side effects noted with baclofen and gabapentin treatments were similar.

CONCLUSION

A variety of drugs are used to treat acquired nystagmus in the UK. Baclofen and gabapentin are the drugs most commonly used and are reported to cause significant improvement in symptoms and VA. Better knowledge of the action of drugs in nystagmus is needed to establish guidelines and to give patients wider access to treatment.

Authors+Show Affiliations

Ophthalmology Group, Department of Ophthalmology, University Hospitals of Leicester, Leicester, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

16732211

Citation

Choudhuri, I, et al. "Survey of Management of Acquired Nystagmus in the United Kingdom." Eye (London, England), vol. 21, no. 9, 2007, pp. 1194-7.
Choudhuri I, Sarvananthan N, Gottlob I. Survey of management of acquired nystagmus in the United Kingdom. Eye (Lond). 2007;21(9):1194-7.
Choudhuri, I., Sarvananthan, N., & Gottlob, I. (2007). Survey of management of acquired nystagmus in the United Kingdom. Eye (London, England), 21(9), 1194-7.
Choudhuri I, Sarvananthan N, Gottlob I. Survey of Management of Acquired Nystagmus in the United Kingdom. Eye (Lond). 2007;21(9):1194-7. PubMed PMID: 16732211.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Survey of management of acquired nystagmus in the United Kingdom. AU - Choudhuri,I, AU - Sarvananthan,N, AU - Gottlob,I, Y1 - 2006/05/26/ PY - 2006/5/30/pubmed PY - 2008/3/4/medline PY - 2006/5/30/entrez SP - 1194 EP - 7 JF - Eye (London, England) JO - Eye (Lond) VL - 21 IS - 9 N2 - PURPOSE: To determine the current management of acquired nystagmus by ophthalmologists and neurologists. METHODS: Questionnaires were sent to ophthalmologists (850) and neurologists (434) in the United Kingdom. Estimated numbers of patients seen with acquired nystagmus, treatment options used, and the results of treatment of the patients were collected. RESULTS: Response rate was 37% for ophthalmologists and 34% for neurologists. The most common causes of acquired nystagmus were estimated to be multiple sclerosis and stroke. 58% of ophthalmologists and 94.5% of neurologists reported seeing patients with nystagmus. The most commonly used medical treatment was gabapentin and baclofen. Other drugs used were clonazepam, carbamazepine, benzhexol, ondansetrone, buspirone, memantine, and botulinum toxin (n=3). Eleven ophthalmologists and 52 neurologists noted symptomatic improvement with medical treatment. Eleven ophthalmologists and 44 neurologists noted improvement in visual acuity (VA). Occurrence of side effects noted with baclofen and gabapentin treatments were similar. CONCLUSION: A variety of drugs are used to treat acquired nystagmus in the UK. Baclofen and gabapentin are the drugs most commonly used and are reported to cause significant improvement in symptoms and VA. Better knowledge of the action of drugs in nystagmus is needed to establish guidelines and to give patients wider access to treatment. SN - 0950-222X UR - https://www.unboundmedicine.com/medline/citation/16732211/Survey_of_management_of_acquired_nystagmus_in_the_United_Kingdom_ L2 - https://doi.org/10.1038/sj.eye.6702434 DB - PRIME DP - Unbound Medicine ER -